These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 6388073)

  • 1. Pharmacokinetics of intravenous cyclosporine in bone marrow transplant patients. Comparison of two assay methods.
    Yee GC; Kennedy MS; Storb R; Thomas ED
    Transplantation; 1984 Nov; 38(5):511-3. PubMed ID: 6388073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of hepatic dysfunction on oral cyclosporin pharmacokinetics in marrow transplant patients.
    Yee GC; Kennedy MS; Storb R; Thomas ED
    Blood; 1984 Dec; 64(6):1277-9. PubMed ID: 6388664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Marrow transplantation for leukemia and aplastic anemia: two controlled trials of a combination of methotrexate and cyclosporine v cyclosporine alone or methotrexate alone for prophylaxis of acute graft-v-host disease.
    Storb R; Deeg HJ; Whitehead J; Farewell V; Appelbaum FR; Beatty P; Bensinger W; Buckner CD; Clift RA; Doney K
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2608-13. PubMed ID: 3547942
    [No Abstract]   [Full Text] [Related]  

  • 4. Age-dependent cyclosporine: pharmacokinetics in marrow transplant recipients.
    Yee GC; Lennon TP; Gmur DJ; Kennedy MS; Deeg HJ
    Clin Pharmacol Ther; 1986 Oct; 40(4):438-43. PubMed ID: 3530588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclosporine metabolism and pharmacokinetics following intravenous and oral administration in the dog.
    Gridelli B; Scanlon L; Pellicci R; LaPointe R; DeWolf A; Seltman H; Diven W; Shaw B; Starzl T; Sanghvi A
    Transplantation; 1986 Mar; 41(3):388-91. PubMed ID: 3952805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic studies of cyclosporine in marrow transplant recipients. A comparison of three assay methods.
    McGuire TR; Yee GC; Emerson S; Gmur DJ; Carlin J
    Transplantation; 1992 Jun; 53(6):1272-5. PubMed ID: 1604484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation.
    Yee GC; Self SG; McGuire TR; Carlin J; Sanders JE; Deeg HJ
    N Engl J Med; 1988 Jul; 319(2):65-70. PubMed ID: 3288872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cyclosporine in allogeneic bone marrow transplantation in children].
    Kojima S; Fukuda M; Horibe K; Matsuyama K
    Rinsho Ketsueki; 1987 Sep; 28(9):1576-82. PubMed ID: 3325658
    [No Abstract]   [Full Text] [Related]  

  • 9. Oral administration of cyclosporin A for recipients of allogeneic marrow transplants: implications of clinical gut dysfunction.
    Atkinson K; Biggs JC; Britton K; Short R; Mrongovius R; Concannon A; Dodds A
    Br J Haematol; 1984 Feb; 56(2):223-31. PubMed ID: 6362711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclosporine disposition in the dog. Comparison of radioimmunoassay with high-performance liquid chromatographic assay and pharmacokinetics following intravenous administration.
    Buice RG; Gurley BJ; Stentz FB; Sidhu P; McClellan T; Williams JW
    Transplantation; 1985 Nov; 40(5):483-8. PubMed ID: 4060219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cyclosporine as prophylaxis for graft versus host disease in adults undergoing allogeneic bone marrow transplantation].
    Matsushita T; Akatsuka Y; Towatari M; Takeyama K; Miyamura K; Sugihara T; Minami S; Kodera Y
    Rinsho Ketsueki; 1989 Apr; 30(4):429-36. PubMed ID: 2671437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Six weeks of continuous intravenous cyclosporine and short-course methotrexate as prophylaxis for acute graft-versus-host disease after allogeneic bone marrow transplantation.
    Beelen DW; Quabeck K; Kaiser B; Wiefelspütz J; Scheulen ME; Graeven U; Grosse-Wilde H; Sayer HG; Schaefer UW
    Transplantation; 1990 Sep; 50(3):421-7. PubMed ID: 2402791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marrow graft rejection and veno-occlusive disease of the liver in patients with aplastic anemia conditioned with cyclophosphamide and cyclosporine.
    Deeg HJ; Shulman HM; Schmidt E; Yee GC; Thomas ED; Storb R
    Transplantation; 1986 Nov; 42(5):497-501. PubMed ID: 3538535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.
    Winston DJ; Antin JH; Wolff SN; Bierer BE; Small T; Miller KB; Linker C; Kaizer H; Lazarus HM; Petersen FB; Cowan MJ; Ho WG; Wingard JR; Schiller GJ; Territo MC; Jiao J; Petrarca MA; Tonetta SA
    Bone Marrow Transplant; 2001 Jul; 28(2):187-96. PubMed ID: 11509937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective trial of mycophenolate mofetil-cyclosporine A prophylaxis for acute GVHD after G-CSF stimulated allogeneic bone marrow transplantation with HLA-identical sibling donors in patients with severe aplastic anemia and hematological malignancies.
    Ostronoff F; Ostronoff M; Souto-Maior AP; Domingues M; Sucupira A; Manso DA; de Lima AK; Monteiro PG; Florêncio R; Calixto R
    Clin Transplant; 2009; 23(1):33-8. PubMed ID: 18727660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of cyclosporine assay methodology in the immediate postoperative period of renal transplantation.
    Morse GD; Holdsworth MT; Walshe JJ
    Ther Drug Monit; 1989; 11(3):238-45. PubMed ID: 2658209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclosporine and methylprednisolone after allogeneic marrow transplantation: association between low cyclosporine concentration and risk of acute graft-versus-host disease.
    Przepiorka D; Shapiro S; Schwinghammer TL; Bloom EJ; Rosenfeld CS; Shadduck RK; Venkataramanan R
    Bone Marrow Transplant; 1991 Jun; 7(6):461-5. PubMed ID: 1873593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunologic reactivity in marrow graft recipients receiving cyclosporine to prevent graft-versus-host disease.
    Von Fliedner VE; Jeannet M; Gratwohl A; Pongratz G; Neri C; Nissen C; Muller M; Osterwalder B; Speck B
    Transplantation; 1983 Aug; 36(2):125-30. PubMed ID: 6349034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal cyclosporine clearance in marrow transplant recipients: age-related variation.
    Yee GC; Mills G; Schaffer R; Lennon TP; Kennedy MS; Deeg HJ
    J Clin Pharmacol; 1986; 26(8):658-61. PubMed ID: 3540031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia.
    Storb R; Deeg HJ; Whitehead J; Appelbaum F; Beatty P; Bensinger W; Buckner CD; Clift R; Doney K; Farewell V
    N Engl J Med; 1986 Mar; 314(12):729-35. PubMed ID: 3513012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.